| Description | DS45500853, an estrogen-related receptor α (ERRα) agonist, acts as an inhibitor of the binding interaction between receptor-interacting protein 140 (RIP140) corepressor peptide (10 nM) and GST-ERRα ligand-binding domain (LBD; 1.2 μM), exhibiting an IC50 of 0.80 μM. This compound holds potential for research pertaining to metabolic disorders, particularly type 2 diabetes mellitus (T2DM). |
| In vitro | DS45500853 (compound 5c; 0.002, 0.006, 0.017, 0.051, 0.015, 0.046, 1.4, 4.2, 12.5 μg/mL; 18 h) inhibits the transcriptional activity of full-length ERRα in MG63 cells with an EC 50 of 5.4 μM[1].DS45500853 binds in the ligand-binding pocket (LBP) of the ERRα LBD as inverse agonist II[1]. |
| molecular weight | 284.355 |
| Molecular formula | C18H20O3 |
| CAS | 2735803-28-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| References | 1. Shinozuka T, et al. Discovery of a Novel Class of ERRα Agonists. ACS Med Chem Lett. 2021 Apr 21;12(5):817-821. |